Prior studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may be linked with higher cardiovascular risks, but few have assessed potential different cardiovascular risk between NSAID classes or across individual NSAIDs.
Prior studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may be linked with higher cardiovascular risks, but few have assessed potential different cardiovascular risk between NSAID classes or across individual NSAIDs.
A British Journal of Clinical Pharmacology study including 55,629 patients with hypertension in a Taiwanese database did not observe different cardiovascular risks in patients who received cyclooxygenase-2 enzyme selective NSAIDs or nonselective NSAIDs during 4 weeks of follow-up.
The study also found no apparent difference in cardiovascular risk when comparing celecoxib with diclofenac, ibuprofen, or naproxen, although a significantly increased risk was observed when comparing celeocxib with mefenamic acid.
“Our results provide important information about the comparative safety of alternative NSAID use in patients with hypertension in real-world settings. Under low-to-moderate daily dose and a short-term treatment period, most commonly used NSAIDs have similar cardiovascular safety profiles,” said co-author Dr. Chia-Hsuin Chang, of the National Taiwan University Hospital.
Additional Information
Link to Study: http://onlinelibrary.wiley.com/doi/10.1111/bcp.13537/full
About Journal
The British Journal of Clinical Pharmacology (BJCP) contains papers and reports on all aspects of drug action in humans: invited review articles, original papers and correspondence. The journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry.
Penny Smith
+44 (0) 1243 770448
sciencenewsroom@wiley.com